Clovis Oncology is advancing the fight against cancer. Founded in 2009, Clovis Oncology is a commercial-stage biotechnology company focused on acquiring, developing and commercializing cancer treatments in the United States, Europe and other international markets. Our pursuit is to improve the lives of people living with cancer. We believe our approach to precision medicine—to deliver the right drug to the right patient at the right time—represents the future of cancer therapy. Our product development programs generally target specific subsets of cancer, and we seek to simultaneously develop, with partners, for those indications that require them, diagnostic tools intended to direct a compound in development to the patients most likely to benefit from their use. Through these collaborations, we have the flexibility to choose the most appropriate technology for each program, and the expertise to gain regulatory approvals and support global commercialization that will parallel Clovis’ regulatory and commercialization paths. Clovis Oncology’s management team has extensive experience in the development of novel cancer therapies and a shared commitment to the company’s vision for meaningful improvements in the lives of patients with cancer. Clovis Oncology (NASDAQ: CLVS) is headquartered in Boulder, Colorado. Please visit our website for more information, including additional office locations in the U.S. and Europe.